RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of an advanced, malignant, solid tumor(s) with all standard treatment options having been exhausted or declined. * Eastern Cooperative Group (ECOG) performance status is 0-2 at Screening. * Measurable disease per RECIST v1.1 by radiographic techniques * Acceptable liver function, serum creatinine and hematological status * Female subjects of childbearing potential, and male subjects with partners of childbearing potential, must agree to use medically acceptable methods of contraception beginning on Study Day 1 and continuing until at least four weeks after administration of the subject's final dose of RRx-001. * Subjects with brain metastases are eligible Exclusion Criteria: * Concurrent anticancer therapy; however, radiotherapy is allowed * Any history of hypersensitivity to irinotecan * Cholangitis that required treatment or intervention within 4 weeks of study enrollment * Bilirubin \> 2.0 mg/dL * Serious medical or psychiatric illness likely to interfere with participation in this clinical study * If female, subject is pregnant and/or breastfeeding. * UGT1A1\*28 homozygote or heterozygote * BMI \>35